Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma

BACKGROUND: According to data estimated by the WHO, primary liver cancer is currently the fourth most common malignant tumor and the second leading cause of death around the world. Hepatocellular carcinoma (HCC) is one of the most common primary liver malignancies, so effective therapy is highly des...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Bonan, Dong, Zhipeng, Liu, Weixing, Lou, Fangning, Wang, Qiyan, Hong, Hao, Wang, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088584/
https://www.ncbi.nlm.nih.gov/pubmed/33933077
http://dx.doi.org/10.1186/s12951-021-00865-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088584/
https://www.ncbi.nlm.nih.gov/pubmed/33933077
http://dx.doi.org/10.1186/s12951-021-00865-w

Ejemplares similares